Physician profile
William Wirshing
NPI 1265621601
$204,857.40
in general payments reported to CMS, 2019-2025
14 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $9,390 · 2021: $32K · 2022: $40K · 2023: $51K · 2024: $22K · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Consulting Fee: $4,860 · Travel and Lodging: $2,887 · Food and Beverage: $1,873 · Education: $54.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,981.00 |
| Consulting Fee | $4,860.00 |
| Travel and Lodging | $2,886.88 |
| Food and Beverage | $1,873.31 |
| Education | $54.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129,260.30 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $25,848.08 | 2019-2022 | |
| Otsuka Pharmaceutical Co., Ltd. | $16,715.19 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $11,726.38 | 2019-2023 | |
| Alkermes, INC. | $11,549.50 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $6,820.34 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $2,127.93 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $532.32 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $114.26 | 2024 | Cobenfy |
| Vanda Pharmaceuticals INC. | $59.73 | 2020-2022 | |
| Indivior INC. | $44.94 | 2019-2022 | |
| Abbvie INC. | $22.76 | 2023 | Vraylar |
| Lundbeck LLC | $21.08 | 2024 | Rexulti |
| Bausch Health US, LLC | $14.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Wirshing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.